TTY Biopharm Company Limited

As of June 30, 2026, TTY Biopharm Company Limited carries a market capitalization of 18.82B, placing it among publicly traded companies globally. Its enterprise value stands at 18.30B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

TTY Biopharm Company Limited's next confirmed earnings release is scheduled for October 30, 2026.

As of June 30, 2026, TTY Biopharm Company Limited has 248.65M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, TTY Biopharm Company Limited maintains a current ratio of 2.13, meaning it holds 2.1x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, TTY Biopharm Company Limited recorded 341.40M in income tax expense.

As of the close on October 22, 2026, TTY Biopharm Company Limited's stock has declined approximately 1.47% over the past 52 weeks. The 50-day moving average sits at 78.65, while the 200-day moving average is 78.17.

As of June 30, 2026, TTY Biopharm Company Limited holds 3.38B in cash and equivalents against 2.07B in total debt, resulting in a net debt position of -873.11M. Total book value stands at 6.96B, with working capital of 3.41B providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, TTY Biopharm Company Limited paid dividends of -0.14 per share.

TTY Biopharm Company Limited's most recent stock split took place on August 13, 2014 with a 1000:1067 split ratio.